HPV vaccine combo shows promise against head and neck cancer in early trial
NCT ID NCT05286060
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining an HPV DNA vaccine with immunotherapy drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18 before surgery. About 56 adults with resectable tumors will receive one of three treatment combinations. The main goal is to see if the tumor has less than 10% living cancer cells after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?